Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database
Authors' conclusion
This is the first nation-level analysis that shows estimated and real-life direct cost-savings for TNFi biosimilars.
Study context
- Population
- Patients with rheumatic musculoskeletal diseases (RMDs) treated with tumour necrosis factor inhibitors (TNFi) in Poland12,687 treatment courses
- Exposure
- Biosimilar TNFi: estimated vs real-life savings
- Outcome
- Estimated and real-life savings for public payer
- Follow-up
- 8-year perspective
Methodological detailsnationwide database, real-world evidence, 8-year perspective, public payer perspective
- Nationwide database
- Real-world evidence
- 8-year perspective
- Public payer perspective
Main finding
As reported in the abstract
Savings for public payer
Estimated total savings for TNFi
over €243 million
Estimated savings attributed to treatment cost reduction in RMDs
over €166 million
Real-life total savings for TNFi
€133 million
Real-life savings in RMDs
€107 million
Observational data: associations, not effects.
Further findings
Share of total savings generated by rheumatology sector
- Rheumatology share of total savings across models, depending on scenario
- between 68% and 92%
Decrease in mean annual cost of treatment
- Overall decrease in mean annual cost of treatment in the study frame
- between 75% and 89%
Hypothetical additional patients with RMDs treatable if all savings reinvested in TNFi · 2021
- Hypothetical total patients with RMDs treatable
- almost 45 000
Original publication
Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database. Ann Rheum Dis. Published 16 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →